Applied Genetics Discovery is attempting to convert the findings from its discovery research, determining genes causing the major diseases, into products and services to help the maximum number of patients in the shortest period of time. The Company has already filed a substantial number of provisional patents which it believes will become the basis for therapeutic drugs, diagnostics and treatment regimes utilizing already approved drugs for new indications. End Stage Renal Disease has been an area of primary focus since inception. Over time, the number of genetic diseases will be expanded to include a wider range of targets. The Company's focus will include Class 5, therapeutic drugs, where it believes it will be able to preliminarily determine targets that are implicated in major genetic based diseases, such as end stage renal disease. The goal is to identify how to prevent or to forstall the onset of major diseases.